

Professor Wendy Susan Stevens – Biography

Professor and Head of Department of Molecular Medicine and Haematology, National Health Laboratory Services and University of the Witwatersrand
Head of Priority Programs at National Health Laboratory Services

Supporting References

1. Glencross, D.K., B.V. Mendelow, and W.S. Stevens, *Laboratory monitoring of HIV/AIDS in a resource-poor setting*. S Afr Med J, 2003. **93**(4): p. 262-3.
2. Glencross, D.K., et al., *The challenge of laboratory monitoring of HIV*. S Afr Med J, 2002. **92**(4): p. 248.
3. Sherman, G.G., et al., *Diagnosis of human immunodeficiency virus infection in perinatally exposed orphaned infants in a resource-poor setting*. Pediatr Infect Dis J, 2000. **19**(10): p. 1014-5.
4. Sherman, G.G., G. Stevens, and W.S. Stevens, *Affordable diagnosis of human immunodeficiency virus infection in infants by p24 antigen detection*. Pediatr Infect Dis J, 2004. **23**(2): p. 173-6.
5. Sherman, G.G., et al., *Dried blood spots improve access to HIV diagnosis and care for infants in low-resource settings*. J Acquir Immune Defic Syndr, 2005. **38**(5): p. 615-7.
6. Stevens, W., et al., *Performance of a novel human immunodeficiency virus (HIV) type 1 total nucleic acid-based real-time PCR assay using whole blood and dried blood spots for diagnosis of HIV in infants*. J Clin Microbiol, 2008. **46**(12): p. 3941-5.
7. Stevens W., et al., *Revised guidelines for diagnosis of perinatal HIV-1 infection in South Africa*. Southern African Journal of HIV Medicine, 2006(22): p. 24-28.
8. Stevens W. and Sherman G.G, *Approaches to Early Infant Diagnosis of HIV*. In: *From the Ground Up: Building Comprehensive HIV/AIDS Care Programs in resource-limited settings*. Marlink RG, Teitelman SJ, editors. Vol. 2. 2009: Elizabeth Glaser Pediatric AIDS Foundation: 821-828. 807-819.
9. Stevens, W., et al., *Role of the laboratory in ensuring global access to ARV treatment for HIV-infected children: consensus statement on the performance of laboratory assays for early infant diagnosis*. Open AIDS J, 2008. **2**: p. 17-25.
10. Driver, G.A., et al., *Low risk of contamination with automated and manual excision of dried blood spots for HIV DNA PCR testing in the routine laboratory*. J Virol Methods, 2007. **146**(1-2): p. 397-400.
11. Stevens, W., et al., *Evaluating new CD4 enumeration technologies for resource-constrained countries*. Nature Reviews Microbiology, 2008. **S29-S38**.
12. Glencross, D.K., et al., *Large-scale affordable PanLeucogated CD4+ testing with proactive internal and external quality assessment: in support of the South African national comprehensive care, treatment and management programme for HIV and AIDS*. Cytometry B Clin Cytom, 2008. **74 Suppl 1**: p. S40-51.
13. Glencross, D.K., et al., *African regional external quality assessment for CD4 T-cell enumeration: development, outcomes, and performance of laboratories*. Cytometry B Clin Cytom, 2008. **74 Suppl 1**: p. S69-79.
14. Glencross D, et al. *Encouraging Point-of-Care PIMA CD4 Testing Performance in a Laboratory Setting: Johannesburg, South Africa*. in *17th CROI*. 16-19 Feb 2010. San Francisco.

15. Scott, L., E, et al. *A comparison of the Guava Personal Cell Analyser (PCA) with PLG CD4 T cell enumeration: A pilot evaluation.* in *11th Conference on Retroviruses and Opportunistic infections*,. 2004. San Francisco, USA.
16. Stevens, G., et al., *Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa.* J Clin Microbiol, 2005. **43**(2): p. 857-61.
17. Stevens, G., et al. *Affordable HIV-1 monitoring: A direct comparison of an improved p24 antigen assay and the Roche Amplicor monitoring assay in 2nd IAS Conference on HIV pathogenesis and treatment 13-16th July, 2003.* Paris, France.
18. Stevens, W., P. Horsfield, and L.E. Scott, *Evaluation of the performance of the automated NucliSENS easyMAG and EasyQ systems versus the Roche AmpliPrep-AMPLICOR combination for high-throughput monitoring of human immunodeficiency virus load.* J Clin Microbiol, 2007. **45**(4): p. 1244-9.
19. Stevens, W., et al., *Evaluation of the NucliSens EasyQ assay in HIV-1-infected individuals in South Africa.* J Virol Methods, 2005. **124**(1-2): p. 105-10.
20. Stevens, W.S. and T.M. Marshall, *Challenges in implementing HIV load testing in South Africa.* J Infect Dis, 2010. **201 Suppl 1**: p. S78-84.
21. Stevens, W.S., L.E. Scott, and S.M. Crowe, *Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings.* J Infect Dis, 2010. **201 Suppl 1**: p. S16-26.
22. Glencross, D.K., et al., *CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort.* Cytometry B Clin Cytom, 2008. **74 Suppl 1**: p. S131-40.
23. Scott, L., S. Carmona, and W. Stevens, *Performance of the new Roche Cobas AmpliPrep-Cobas TaqMan version 2.0 human immunodeficiency virus type 1 assay.* J Clin Microbiol, 2009. **47**(10): p. 3400-2.
24. Scott, L.E., et al. *Semi-quantification of the APTIMA HIV-1 Screening assay with GEN-Probes' high throughput TIGRIS analyser for application in subtype C HIV-1 viral load monitoring.* in *5th IAS Conference on HIV Pathogenesis, Treatment and Prevention*,. 2009 July. Cape Town, South Africa.
25. Scott, L.E., et al., *Abbott RealTime HIV-1 m2000rt viral load testing: manual extraction versus the automated m2000sp extraction.* J Virol Methods, 2011. **172**(1-2): p. 78-80.
26. Hamers, R.L., et al., *Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.* Clin Infect Dis, 2012. **54**(11): p. 1660-9.
27. Stevens, W.S., *Slow accumulation of HIV resistance mutations: implications for resource-limited settings?* J Infect Dis, 2009. **200**(5): p. 670-2.
28. Wallis, C., et al., *Antiretroviral-Drug Resistance Patterns of Patients on the South African Roll-out program: Two Johannesburg Clinic Experiences.* In: *CROI 2007, 14th Conference on retroviruses and opportunistic infections*,. Los Angeles. 2007.
29. Wallis C, et al. *Affordable resistance test for Africa (ARTA): DBS storage and extraction conditions for HIV resistance testing.* in *5th IAS Conference on HIV Pathogenesis and Treatment*. 2009.
30. Wallis, C.L., et al., *Emergence of drug resistance in HIV-1 subtype C infected children failing the South African national antiretroviral roll-out program.* Pediatr Infect Dis J, 2009. **28**(12): p. 1123-5.
31. Wallis, C.L., et al., *Evaluation of an oligonucleotide ligation assay for detection of mutations in HIV-1 subtype C individuals who have high level resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors.* J Virol Methods, 2005. **125**(2): p. 99-109.
32. Wallis, C.L., et al., *Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa.* J Acquir Immune Defic Syndr. **53**(4): p. 480-4.

33. Wallis, C.L., et al., *Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1*. J Virol Methods. **163**(2): p. 505-8.
34. Sigaloff, K.C., et al., *Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries*. Clin Infect Dis, 2012. **54 Suppl 4**: p. S294-9.
35. Sigaloff, K.C., et al., *Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa*. J Acquir Immune Defic Syndr, 2011. **58**(1): p. 23-31.
36. Sigaloff, K.C., et al., *Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa*. J Infect Dis, 2012. **205**(11): p. 1739-44.
37. Hamers, R.L., et al., *The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa*. Antivir Ther, 2008. **13**(5): p. 625-39.
38. Hamers, R.L., et al., *Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific*. Int J Epidemiol, 2012. **41**(1): p. 43-54.
39. Hamers, R.L., et al., *Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study*. Lancet Infect Dis, 2012. **12**(4): p. 307-17.
40. Hamers, R.L., et al., *HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia*. J Acquir Immune Defic Syndr, 2010. **55**(1): p. 95-101.
41. Hamers, R.L., et al., *Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review*. Antivir Ther, 2009. **14**(5): p. 619-29.
42. Hamers, R.L., et al., *Building capacity for the assessment of HIV drug resistance: experiences from the PharmAccess African Studies to Evaluate Resistance network*. Clin Infect Dis, 2012. **54 Suppl 4**: p. S261-5.
43. Hamers, R.L., et al., *HIV-1 drug resistance in antiretroviral-naïve individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study*. Lancet Infect Dis, 2011. **11**(10): p. 750-9.
44. Bartlett, J.A., et al., *Lopinavir/ritonavir Monotherapy After Virologic Failure of First-line Antiretroviral Therapy in Resource-limited Settings*. AIDS, 2012.
45. Brehm, J.H., et al., *Frequent Emergence of N348I in HIV-1 Subtype C Reverse Transcriptase with Failure of Initial Therapy Reduces Susceptibility to Reverse-Transcriptase Inhibitors*. Clin Infect Dis, 2012.
46. Nahid, P., et al., *Clinical research and development of tuberculosis diagnostics: moving from silos to synergy*. J Infect Dis, 2012. **205 Suppl 2**: p. S159-68.
47. Scott, L., E, et al., *Dried Culture Spots for Xpert MTB/RIF External Quality Assessment, Abstract MOPE147*
in *International AIDS Society*. 2011: Rome, Italy.
48. Scott, L.E., et al., *Exploring the Value of the Xpert MTB/RIF Probe Frequencies and Cycle Threshold Data for Surveillance Purposes, abstract number 924.*, in *19th Conference of Retroviruses and Opportunistic infections, Seattle, USA*. 2012.
49. Scott, L.E., et al., *The use of a pre-qualification panel for rapid scale-up of HIV viral load testing*, in *5th SA AIDS Conference*. 7-10 June 2011: Durban South Africa.
50. Stevens, W., *Taking the first steps: Xpert MTB/RIF Implementation in public sector in South Africa: Lessons Learned*. IAS, Rome, July 2011 (oral presentation). 2011.
51. Stevens, W., *GeneXpert Implementation in South Africa Clinical and Cost Implications*. ECCMID, London, April 2012. 2012.
52. Van Rie, A., et al., *Xpert((R)) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope?* Expert Rev Mol Diagn. **10**(7): p. 937-46.

53. Meyer-Rath G, S.K., Long L, MacLeod W, Sanne I, Stevens W, Pillay S, Pillay Y, Rosen S, *The impact and cost of scaling up GeneXpert MTB/RIF in South Africa*. PLOS ONE, accepted, 2012.
54. Schnippel, K., et al., *Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa*. Trop Med Int Health, 2012.
55. Clouse, K., et al., *Implementation of Xpert MTB RI?RIF for routine point of care diagnosis of tuberculosis at the primary health care level*. Accepted to PLOS Medicine, March 2012, 2012.
56. Glencross, D.K., et al., *Performance evaluation of the Pima point-of-care CD4 analyser using capillary blood sampling in field tests in South Africa*. J Int AIDS Soc, 2012. **15**: p. 3.
57. Palamountain, K.M., et al., *Perspectives on introduction and implementation of new point-of-care diagnostic tests*. J Infect Dis, 2012. **205 Suppl 2**: p. S181-90.
58. Hamers, R.L., et al., *Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis*. AIDS, 2012.
59. Rosen, S., et al., *The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data*. J Int AIDS Soc, 2011. **14**: p. 24.
60. Stevens, W., *Good clinical laboratory practice (GCLP): the need for a hybrid of good laboratory practice and good clinical practice guidelines/standards for medical testing laboratories conducting clinical trials in developing countries*. Qual Assur, 2003. **10(2)**: p. 83-9.
61. Sanne, I., et al., *Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial*. Lancet, 2010. **376(9734)**: p. 33-40.
62. Gilmour, J.W., et al., *Laboratory expansion to large-scale international HIV preventive vaccine trials*. Curr Opin HIV AIDS, 2007. **2(3)**: p. 201-206.